3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
4
Lung Neoplasms
4
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Camurati-Engelmann Syndrome
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Anatomic Stage II Breast Cancer AJCC v8
1
Interventions
Gemcitabine
58
Cisplatin
41
Capecitabine
27
Oxaliplatin
25
durvalumab
16
Fluorouracil
16
Leucovorin
15
S 1 (combination)
11
lenvatinib
10
Nivolumab
10
Irinotecan
10
pembrolizumab
8
apatinib
8
Immune Checkpoint Inhibitors
7
130-nm albumin-bound paclitaxel
7
tremelimumab
6
Bevacizumab
6
camrelizumab
5
Trastuzumab
5
Drug Therapy
5
Blood Specimen Collection
5
Albumin-Bound Paclitaxel
5
tislelizumab
4
irinotecan sucrosofate
4
Taxes
4
Liquid Biopsy
4
Folfox protocol
4
toripalimab
3
surufatinib
3
gemcitabine-oxaliplatin regimen
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Biliary Tract Neoplasms
×
bintrafusp alfa protein, human
×
Clear all
NCT04727541
2022-05-23
NEOBIL
AIO-Studien-gGmbH
Phase 2
Terminated
3 enrolled